Drug · DIN 02328674 · Radiopharmaceutical
ZEVALIN
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since December 6, 2023; first marketed September 12, 2018.
- Drug Identification Number (DIN)
- 02328674
- Company (DIN owner)
- Auro Pharma Inc.Woodbridge, Ontario, Canada
- Schedule
- Schedule C
- Dosage form
- Kit; Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Ibritumomab tiuxetan (90y) V10XX02
- Class
- Radiopharmaceutical
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IBRITUMOMAB TIUXETAN | 3.2 MG | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 17, 2023: NOC 32284New Drug Submission (NDS) · Administrative - Administrative Change in Product Ownership